HomeCompareAVID vs JNJ

AVID vs JNJ: Dividend Comparison 2026

AVID yields 7.40% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVID wins by $2.2K in total portfolio value
10 years
AVID
AVID
● Live price
7.40%
Share price
$27.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.6K
Annual income
$1,182.03
Full AVID calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — AVID vs JNJ

📍 AVID pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVIDJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVID + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVID pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVID
Annual income on $10K today (after 15% tax)
$628.58/yr
After 10yr DRIP, annual income (after tax)
$1,004.73/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, JNJ beats the other by $3,032.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVID + JNJ for your $10,000?

AVID: 50%JNJ: 50%
100% JNJ50/50100% AVID
Portfolio after 10yr
$31.5K
Annual income
$2,965.95/yr
Blended yield
9.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AVID
Analyst Ratings
6
Buy
9
Hold
1
Sell
Consensus: Hold
Price Target
$27.05
+0.0% upside vs current
Range: $27.05 — $27.05
Altman Z
-1.9
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVID buys
0
JNJ buys
0
No recent congressional trades found for AVID or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVIDJNJ
Forward yield7.40%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$32.6K$30.5K
Annual income after 10y$1,182.03$4,749.88
Total dividends collected$9.6K$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$27.05$228.73

Year-by-year: AVID vs JNJ ($10,000, DRIP)

YearAVID PortfolioAVID Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,440$739.51$10,594$274.49+$846.00AVID
2$13,031$790.62$11,294$360.69+$1.7KAVID
3$14,785$841.68$12,133$476.91+$2.7KAVID
4$16,712$892.49$13,156$635.42+$3.6KAVID
5$18,825$942.85$14,432$854.61+$4.4KAVID
6$21,135$992.56$16,056$1,162.76+$5.1KAVID
7$23,656$1,041.47$18,175$1,604.53+$5.5KAVID
8$26,401$1,089.43$21,009$2,252.68+$5.4KAVID
9$29,386$1,136.32$24,911$3,229.73+$4.5KAVID
10$32,625$1,182.03$30,458$4,749.88+$2.2KAVID

AVID vs JNJ: Complete Analysis 2026

AVIDStock

Avid Technology, Inc., together with its subsidiaries, develops, markets, sells, and supports software and integrated solutions for video and audio content creation, management, and distribution worldwide. The company's video products and solutions include the Media Composer, a cloud-enabled solution used to edit video content; Avid NEXIS shared storage systems; Maestro solutions for the integration of virtual sets, augmented reality, and video wall control into existing workflows; AirSpeed 5000 and AirSpeed 5500 on-air server solutions; and MediaCentral, a media production suite. Its audio products and solutions comprise Pro Tools digital audio software solutions to facilitate the audio production process; Sibelius solution to create, edit, and publish musical scores; S6 line of complementary control surfaces and consoles; S1 and S4 audio control surfaces; and VENUE | S6L live sound system for mixing audio for live sound reinforcement. The company also provides Avid Link, a mobile application to connect with other artists, producers, mixers, composers, editors, videographers, movie makers, and graphic designers; FastServe video server that assists broadcasters in making the move to UHD and IP based workflows with a new and modular architecture; and hardware products, such as I/O devices, interfaces, and audio and video processing equipment. In addition, it offers various maintenance contracts and support services; professional services, such as workflow design and consulting, program and project management, system installation and commissioning, and custom development and role-based product level training; and public and private training to customers and alliance partners, as well as develops and licenses curriculum content for use by third party Avid Learning partners to deliver training to customers, users, and alliance partners. The company was incorporated in 1987 and is headquartered in Burlington, Massachusetts.

Full AVID Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AVID vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVID vs SCHDAVID vs JEPIAVID vs OAVID vs KOAVID vs MAINAVID vs ABBVAVID vs MRKAVID vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.